What you will learn
- Peptide signaling and receptor pathways
- Dosing principles and safety considerations
- Application across performance, recovery, and metabolic optimization
- Aesthetic medicine and longevity-focused care
- Protocol design and treatment planning
- Patient communication and ethical marketing
- Documentation standards and regulatory awareness
- Case-based discussions and real-world clinical scenarios
Curriculum
Module 1 — Peptide Science
- Peptide signaling and receptor pathways 90 min
- Dosing principles and safety 90 min
- Patient selection and candidacy 60 min
- Documentation and regulatory awareness 60 min
Module 2 — Clinical Application
- Performance, recovery, and metabolic optimization 90 min
- Aesthetic medicine and longevity care 90 min
- Protocol design and treatment planning 90 min
- Case discussions and clinical scenarios 120 min
Instructor
Clinically focused program built on the Genademy evidence and regulatory framework. Faculty details announced with the course launch.
Peptide regulatory FAQ
The questions clinicians ask first are rarely about protocols. They are about what may be compounded, what a supplier's paperwork actually certifies, and what your own board allows. The answers below are the framework. Your state's rules govern your practice.
What is a 503A compounding pharmacy?
A 503A pharmacy is a state-licensed pharmacy that compounds a drug for an identified patient after receiving a patient-specific prescription from a licensed prescriber. It works under state board of pharmacy oversight and the federal conditions in section 503A of the Food, Drug, and Cosmetic Act. Compounded drugs are not reviewed or approved by FDA before they are dispensed, so the pharmacy's process and your prescription are the controls.
How is a 503B outsourcing facility different?
A 503B facility registers with FDA as an outsourcing facility and compounds under current good manufacturing practice. It may compound without patient-specific prescriptions, which is what allows a clinic to hold stock, but it accepts stricter federal requirements: inspection, adverse event reporting, and bulk substances drawn from FDA's 503B bulks list. In short, 503B trades flexibility for federal manufacturing scrutiny.
Does a 503A or 503B source mean a peptide has FDA approval?
No. Compounding is not approval. A peptide made by a registered facility remains an unapproved drug unless that specific product holds an FDA approval of its own. Registration tells you who is accountable for how the drug was made. It does not tell you that FDA reviewed it, and it does not establish that the product is lawful to dispense for a given use in your state.
Does a peptide certificate give me prescribing authority?
No, and two different documents get called a certificate. A certificate of analysis is a supplier's lot document: identity, purity, and where offered, sterility and endotoxin results. A course certificate records completed training. Prescribing authority comes from your professional license and your state's scope of practice. Neither document creates it, and neither one widens it.
What does research use only permit, and what does it not?
Research use only is a labeling designation for material intended for laboratory and analytical work. It permits that use. It does not authorize administration to a person, it does not exempt the material from drug law, and it does not lower the standard of care. A vial labeled research use only is a reagent sold with a supplier disclaimer, not a pharmaceutical supply chain released for human use.
Can I use a research-use-only peptide in a patient?
Not on the strength of the label. Giving a research-use-only product to a patient means using an unapproved drug that was not manufactured or released for human use, and the documentation, consent, and liability consequences land on the prescriber. When a patient asks for a peptide by name, including BPC-157, the first question is what may lawfully be dispensed where you practice, not what a supplier is willing to ship.
How do I check whether a peptide can be compounded at all?
It is a list question rather than a marketing question. Under 503A, a bulk substance must be the subject of a USP or National Formulary monograph, a component of a drug that FDA has approved, or a substance on FDA's 503A bulks list. FDA also maintains a category of substances that should not be compounded at all. Advisory committee recommendations, several peptides among them, are recommendations to FDA and not permission to compound. Read the current list at the time you prescribe, because it changes.
What does my state board require?
Usually more than the federal framework, and differently in every state. Your board of medicine, nursing, or pharmacy sets whether you may prescribe and dispense a compounded product, whether your office may hold stock, what supervision or collaborative agreement a non-physician prescriber needs, what consent and recordkeeping apply, and whether telehealth prescribing is allowed. Some states add statutes specific to regenerative and peptide products. Verify in writing with your own board, for your own license type.
Where can I see where my state stands?
The state-by-state regulatory heat map tracks the permissiveness landscape for peptides, exosomes, stem cells, and biologics across all 50 states plus DC, with the federal framework and enforcement trends alongside it. Treat it as market intelligence, not legal advice: it tells you what to ask your board, and it does not replace asking.
Is completing this course a credential to practice?
No. This program is professional education. A Genademy course certificate records completed training. It is not a license, not a board certification, and not authorization to prescribe or dispense, and nothing in the course changes your scope of practice.